1st Quarter - Report

MEHLMAN CONSULTING, INC. for VIZIENT INC

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Healthcare transparency, costs and access to affordable medication and other healthcare items and services.

LobbyistCovered position, as disclosed
DEAN ROSEN —

Contacted: Office of the Vice President of the United States; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); SENATE; White House Office; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Health Issues HCR

Healthcare coverage; prescription drug costs; group purchasing issues; drug shortage issues. 340B Drug Pricing Program. S. 1895, No Surprises Act. S.2543 - Prescription Drug Pricing Reduction Act of 2019 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R. 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act - Public Law No: 116-123 H.R. 6201, the Families First Coronavirus Response Act - Public Law No: 116-127 H.R. 748, the Coronavirus Aid, Relief, and Economic Security (CARES) Act - Public Law No: 116-136

LobbyistCovered position, as disclosed
LAUREN ARONSON —
DEAN ROSEN —

Contacted: Centers For Medicare and Medicaid Services (CMS); White House Office; Office of the Vice President of the United States; HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Bills named: S. 2543 (116th), H.R. 3 (116th), S. 1895 (116th), H.R. 6074 (116th), H.R. 6201 (116th), H.R. 748 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.